|
Clozapine for Treatment-Resistant Mania Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Clozapine for Treatment-Resistant Mania conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Clozapine for Treatment-Resistant Mania Clinical research trials and Clozapine for Treatment-Resistant Mania healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Clozapine for Treatment-Resistant Mania. Clozapine for Treatment-Resistant Mania Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Clozapine for Treatment-Resistant Mania clinical trial. Human subjects often obtain the finest healthcare possible for their Clozapine for Treatment-Resistant Mania condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clozapine for Treatment-Resistant Mania  Clozapine for Treatment-Resistant Mania
Clozapine for Treatment-Resistant Mania
For Condition: Bipolar Disorder
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to evaluate the safety and effectiveness of clozapine as a treatment for the manic phase of bipolar disorder. A significant proportion of manic patients either do not respond adequately to conventional treatment or cannot tolerate the adverse effects associated with therapeutic doses of these agents. Clozapine may be a safe and effective treatment for mania. However, the efficacy of clozapine as an alternative therapy in treatment-resistant bipolar disorder mania has not been extensively researched. The study will be conducted in three phases. Phase 1 is a screening phase that will take place for 2 to 7 days. Participants will undergo a baseline positron emission tomography (PET) scan of the brain at the end of this period. In Phase 2, participants will be randomly assigned to receive either clozapine or placebo (an inactive pill) for 3 weeks. They may also receive lorazepam for the first 10 days of Phase 2. After 3 weeks, patients treated with clozapine will undergo a second PET scan. During Phase 3, participants who received placebo and did not improve will be offered clozapine for 3 weeks. Those who received clozapine and did not improve will receive other treatment for 3 weeks. At the end of Phase 3, participants who were treated with clozapine will have another PET scan.
Details: A significant proportion of manic patients either do not respond adequately to conventional treatment (lithium, valproate or carbamazepine (with or without antipsychotic drugs), or cannot tolerate the adverse effects associated with therapeutic doses of these agents. Thus, a need exists for additional effective treatments. Preliminary studies by our group suggest that clozapine may have antimanic actions and be effective in treatment-resistant bipolar disorder. However, the efficacy of clozapine as an alternative therapy in treatment-resistant mania has never been subjected to definitive study with an adequate number of subjects. Thus, we propose to conduct the largest and only double-blind, placebo-controlled trial to date, of clozapine, in bipolar manic patients who were unresponsive or intolerant to six weeks of treatment with lithium, valproate, carbamazepine and at least one antipsychotic drug. The specific aims of this investigation are to 1) assess the acute treatment efficacy of clozapine in treatment-resistant mania, 2) to investigate the functional anatomical correlates of mania, and 3) to investigate the effects of clozapine treatment on cerebral glucose metabolism and metabolic correlates of effective antimanic, clozapine treatment. Forty-two subjects (two groups of 21 each) will be randomly assigned to treatment with clozapine or placebo for three weeks. We anticipate that a maximum of 33% of patients will be withdrawn from the acute phase of the study due to reasons such as intolerable adverse effects or withdrawal of consent. Thus, we expect the entered sample to yield 14 completed subjects per cell. This sample size will allow for adequate statistical power to test the hypotheses stated above. Patients, ages 18-60, with a diagnosis of bipolar I disorder manic or mixed (with or without psychotic features), will be randomized to double-blind treatment to receive either clozapine (200-550 mg/day) or placebo, for a period of 3 weeks. Following this acute period, the patients will receive either open-label clozapine or treatment as clinically indicated. If clozapine is found effective in treatment-resistant mania, it would be a significant step forward in the treatment of these patients and would have major health implications. In addition, it would establish a gold standard against which newer treatments can be compared to. Finally, glucose metabolism images will be obtained using PET and [F-18] FDG at baseline and following 3 weeks of clozapine treatment to investigate the functional anatomical correlates of mania and to compare drug-induced metabolic changes between responders and nonresponders.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Males or females 18 to 60 years of age; Diagnosis: DSM-IV Bipolar I Disorder, current episode manic or mixed with or without psychotic features as determined by SCID-P. This criteria includes the following diagnoses: 296.4X, Bipolar I Disorder, Most Recent Episode Manic, and 296.6X, Bipolar I Disorder, Most Recent Episode Mixed; YMRS greater than or equal to 20 at Visits 1 and 2; No decrease in total score of YMRS of greater than or equal to 20% during washout (between Visits 1 and 2); Meet criteria for treatment resistance. Patients must have experienced at least two manic or mixed episodes within five years prior to study entry and one manic or mixed episode being within the last 12 months (not including the current episode); DSM-IV rapid cyclers will be permitted to participate in this study; Each patient must have a level of understanding sufficient to agree to all the tests required by the protocol; Each patient must understand the nature of the study and must sign an informed consent document. It is recommended, but not required, that an NIH Advanced Directive form be completed. EXCLUSION CRITERIA: WBC count is less than 3500/mm(3) or history of a myeloproliferative disorder. History of meeting criteria for DSM-IV criteria for schizophrenia or other psychotic disorder; History of DSM-IV substance abuse, including alcohol within the last three months and substance dependence (except nicotine and caffeine) within the past 5 years; Acute or unstable medical illnesses, (e.g., delirium, metastatic cancer, unstable diabetes, decompensated cardiac, hepatic, renal or pulmonary disease, or stroke or myocardial infarction within the last six months); Current pregnancy or plan to become pregnant during the first three months (the duration of the study) in woman of childbearing age; breast-feeding in woman with infants; Previous treatment with clozapine; History of seizures; History of leukopenia or agranulocytosis; Uncorrected hypo- or hyperthyroidism; Elevated thyroid stimulating hormone (TSH) greater than or equal to 5.0 micro U/ml; Concomitant use carbamazepine or other concomitant medication with primarily CNS activity; Has received an investigational drug within 30 days of enrollment. Has received an antidepressant within 4 weeks prior to Visit 1 (8 weeks for fluoxetine); Treatment with an oral antipsychotic drug within 5 half-lives prior to Visit 2; No course of ECT (electroconvulsive therapy) within the preceding 4 weeks to Visit 1; Treatment with an injectable depot neuroleptic within less than one dosing interval prior to Visit 1; Is actively suicidal, and/or has a score of 3 or more on item 3 of the HAMD; Has an acute or chronic illness likely to impair drug absorption, distribution, metabolism or excretion; General MRI exclusion criteria.
Total Enrollment: 42
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020085; 02-M-0085
Study Start Date: January 2, 2002
Record last reviewed: December 8, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029458
Other Bipolar Disorder Studies:
1. Maintenance Therapies in Bipolar Disorders
2. Riluzole and Lithium to treat Depression in Bipolar Disorder
3. Genetic Aspects of Neurologic and Psychiatric Disorders
4. Treatment of Depression in Youth with Bipolar Disorders
5. Does Bipolar Disease Program (BDP) intervention improve long term manic and depressive symptoms.
Related Studies:
Other Bipolar Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Clozapine for Treatment-Resistant Mania
|
|
|
|
|
|
|
|
